Investigational drug · Phase 2
MF-300
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sarcopenia in Elderly.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MF-300"
First trial start
2027
Jan 1, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MF-300", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcopenia in Elderly
Largest trials
Live from ClinicalTrials.gov: studies naming "MF-300" as an intervention, largest first.
- MF-300 for Treatment of Age-Related SarcopeniaPivotal-lookingNot yet recruiting
Epirium Bio Inc.Industry
NCT07921420 · 225 participants (planned) · Start Jan 1, 2027 · Primary completion Jun 1, 2028
Drug: MF-300; Placebo and 1 more · For: Sarcopenia in Elderly
- Single and Multiple Ascending Dosing Administration of MF-300 in Healthy ParticipantsPivotal-lookingCompleted
Epirium Bio Inc.Industry
NCT07613684 · 100 participants · Start Dec 20, 2024 · Primary completion Oct 9, 2025
Drug: MF-300 SAD; Placebo and 2 more · For: Healthy Volunteers
Sites: Marlton, New Jersey; Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Inhibiting 15-PGDH restores redox homeostasis and confers neuroprotection in Parkinson's disease.
Kim YK, Cha YJ, Park SE, et al. · Redox Biol 2026
Also in development for Sarcopenia in Elderly
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.